Law spurs regulators to heed patients’ priorities

Amy Maxmen

Nature, 2012, vol. 487, issue 7406, 154-154

Abstract: US FDA to consider risks and benefits more explicitly in drug approvals.

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/487154a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:487:y:2012:i:7406:d:10.1038_487154a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/487154a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().